-
Dabigatran: Evidence for Thromboembolic Prevention
2026-09-20
The 2015 review by Enriquez and colleagues evaluates dabigatran as the first widely introduced non-vitamin K oral anticoagulant, emphasizing its direct thrombin inhibition, predictable pharmacokinetics, and clinical evidence across thromboembolic disorders. Its practical significance lies in relating trial outcomes to renal clearance, bleeding management, dose selection, and the limitations of replacing warfarin monitoring with a fixed-dose strategy.
-
circRHOBTB3–NONO Axis in Metastatic Prostate Cancer
2026-09-19
A 2025 Cancer Letters study identifies circRHOBTB3 as a prostate cancer suppressor that limits MAOA transcription by retaining NONO in the cytoplasm. Its integrated sequencing, localization, interaction, functional, and circRNA-biogenesis analyses define a regulatory axis with potential biomarker relevance, while also highlighting important limits for clinical translation.
-
14-3-3 Binding Proteins in Autophagy and Cancer
2026-09-18
The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and defines distinct mechanisms linking them to basal autophagy and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, and biochemical validation provides a framework for studying how phosphorylation-dependent protein interactions control protein stability, localization, and cancer-relevant pathways.
-
Ginsenoside Rg2 Protects the Alzheimer’s BBB
2026-09-18
The reference study shows that ginsenoside Rg2 improves Alzheimer’s disease-related blood–brain barrier dysfunction by reducing astrocyte activation, oxidative stress, and TLR4/MyD88/MMP9-associated inflammation. Its combined animal, endothelial, astrocyte, and co-culture design provides a useful framework for studying how neuroinflammation alters tight-junction stability.
-
Autophagy–Metastasis Signature in Colorectal Cancer
2026-09-17
Bai et al. integrate autophagy- and liver metastasis-associated genes with bulk and single-cell transcriptomic analyses to develop a six-biomarker prognostic signature for colorectal cancer. The study links higher molecular risk with immune dysfunction, SPP1-positive M2-like macrophage polarization, CD8+ T-cell exhaustion, and potential resistance to immunotherapy.
-
Ionomycin Calcium Salt in Translational Oncology
2026-09-17
A mechanistic guide to using Ionomycin calcium salt as a controlled calcium perturbation tool for studying apoptosis, bladder cancer biology, and the relationship between calcium stress and ribosome-dependent tumor survival.
-
SNAI1–PIK3R2/p-EphA2 Axis in Thymic Tumors
2026-09-16
A 2024 study identifies SNAI1 as a central regulator of epithelial–mesenchymal transition and cancer stem cell-like properties in thymic epithelial tumors. By integrating transcriptomic, single-cell, chromatin, proteomic, and functional assays, the work connects SNAI1 to a PIK3R2/p-EphA2/GSK3β–β-catenin signaling axis and provides a mechanistic framework for therapeutic investigation.
-
TGF-β, Sca-1, and Mammary Cell Plasticity
2026-09-16
The reference study shows that TGF-β dynamically regulates Sca-1 expression and reshapes the plasticity and tumor-initiating potential of pre-neoplastic mammary epithelial cells. Its key contribution is separating endogenous Smad2/3/4-dependent regulation from the Smad2/3-independent response to exogenous TGF-β, providing a framework for interpreting stem-cell markers as context-dependent states rather than fixed identities.
-
ECL Chemiluminescent Substrate Detection Kit Guide
2026-09-15
The ECL Chemiluminescent Substrate Detection Kit (Enhanced) supports sensitive HRP-based western blot chemiluminescence detection when low-abundance proteins or extended imaging flexibility are needed. It is intended for direct or indirect HRP antibody detection and should not be assumed suitable for alkaline phosphatase, fluorescence, or non-immunoblot assays without separate validation.
-
Tropifexor (LJN452) FXR Research Workflows
2026-09-15
Build reproducible FXR activation, epithelial barrier, and metabolic assays with Tropifexor (LJN452). This workflow-focused guide shows how to connect receptor-level experiments with portal-metabolism findings while avoiding common solvent, timing, and assay-interpretation errors.
-
Gut–Brain Imaging in Chronic Hepatic Encephalopathy
2026-09-14
The 2025 European Journal of Neuroscience study used [18F]PBR146 micro-PET/CT to compare Bifidobacterium and fecal microbiota transplantation in bile duct ligation rats with chronic hepatic encephalopathy. Its main contribution is showing that regional, rather than whole-brain, imaging analysis can detect treatment-associated differences even when behavioral, cytokine, and global uptake measures remain unchanged.
-
Adipose-Neural Signaling in Cardiac Arrhythmia
2026-09-14
Fan et al. developed a stem cell-based coculture model showing that epicardial adipocyte-derived leptin can activate sympathetic neurons, increase neuropeptide Y release, and promote cardiomyocyte arrhythmia through Y1 receptor, NCX, and CaMKII signaling. The study connects cellular mechanism with observations in atrial fibrillation patients and provides a framework for testing pathway-specific interventions while retaining important in vitro and clinical-association limitations.
-
JNJ-10198409: PDGF Receptor Assay Workflows
2026-09-13
Build sharper PDGF-BB signaling assays with JNJ-10198409 by combining concentration-response testing, phospho-receptor kinetics, and longer-term proliferation readouts. This workflow distinguishes direct pathway suppression from delayed cytotoxicity and extends naturally into tumor, angiogenesis, vascular, and fibrotic disorder research.
-
SPP2, Liver Regeneration, and Phosphorylation Fidelity
2026-09-12
The SPP2 liver-regeneration study illustrates how secreted-factor discovery can expose new control points in tissue repair. This thought-leadership article connects that biology to a practical translational risk: phosphatase-driven signal loss during sample handling. It explains how Phosphatase Inhibitor Cocktail 1 (100X in DMSO) can support more faithful Western blotting, kinase assays, and phosphoproteomic analysis while clarifying its limitations and appropriate controls.
-
CKI 7 Dihydrochloride: CK1 Inhibitor Guide
2026-09-11
CKI 7 dihydrochloride is a Casein kinase 1 inhibitor used to interrogate CK1-dependent phosphorylation in biochemical and cell biology research. Its ATP-site mechanism supports pathway studies, but the compound should not be treated as proof that every phenotype is CK1-specific or as evidence for the MAPK10–KRT16 axis.